Alumis Inc. Common Stock
Veridion Score
Composite trend over time
Why is ALMS moving today?
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ALMS.
ALMS insider activity
Alumis Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net buying: $51.1M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | 2026-05-22 | Drappa Jorn | Insider | buy | $5.06 | 15,535 | 59,339 | $79K | SEC Form 4 |
| 2026-05-27 | 2026-05-22 | Drappa Jorn | Insider | buy | $8.84 | 11,317 | 43,804 | $100K | SEC Form 4 |
| 2026-01-13 | 2026-01-09 | AKKARAJU SRINIVAS | Insider | buy | $17.00 | 588,235 | 1,853,488 | $10.0M | SEC Form 4 |
| 2026-01-12 | 2026-01-08 | Foresite Labs, LLC | Insider | buy | $17.00 | 294,117 | 2,908,332 | $5.0M | SEC Form 4 |
| 2026-01-12 | 2026-01-08 | Foresite Labs, LLC | Insider | buy | $17.00 | 117,647 | 5,702,536 | $2.0M | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 33 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moALMS contract awards, year to date.
Public federal awards linked to this ticker.
ALMS lobbying filings, year to date.
Registered lobbying filings matched to Alumis Inc. Common Stock.